<?xml version="1.0" encoding="UTF-8"?>
<p id="p0420">In this regard, it is known SARS-CoV Nps1 induces the expression of interleukin-2 via nuclear factor of activated T cell (NF-AT) activation,
 <xref rid="b0970" ref-type="bibr">
  <sup>194</sup>
 </xref> which can trigger the cytokine storm seen in patients with severe COVID-19 status.
 <xref rid="b0685" ref-type="bibr">
  <sup>137</sup>
 </xref> Another advantage presented by CsA in relation to other anti-inflammatory drugs is its already known anti-CoV action against all genus, including SARS-CoV,
 <xref rid="b0970" ref-type="bibr">194</xref>, 
 <xref rid="b0975" ref-type="bibr">195</xref>, 
 <xref rid="b0980" ref-type="bibr">196</xref> at low and non-cytotoxic micromolar concentrations verified in cell culture assays. This antiviral property is thought to be mediated by the inhibition of cyclophilin-A-dependent viral assembly as well as inhibition of the NF-AT pathway or even by genetic or pharmacological specific inhibition of cyclophilin-D, hindering the viral replication.
 <xref rid="b0970" ref-type="bibr">194</xref>, 
 <xref rid="b0985" ref-type="bibr">197</xref>
</p>
